BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma Meeting Abstract
| Authors: | Follows, G.; Burke, J. M.; Grosicki, S.; Chen, C.; Sanna, A.; Roeker, L. E.; Yi, S.; Munir, T.; de la Cruz, F.; Ferrant, E.; Mátrai, Z.; Ghia, P.; Jurczak, W.; Bosch, F.; Hill, M. E.; Wang, D.; Guntur, A.; Leow, C. C.; Sharman, J. P.; Barr, P. M. |
| Abstract Title: | BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.TPS7582 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: TPS7582 -- Meeting was also available virtually -- Source: Cinahl |
